Product Code: TIPRE00005512
The biopharmaceutical contract manufacturing market size is expected to grow from US$ 40.99 billion in 2024 to US$ 101.05 billion by 2031; it is projected to register a CAGR of 13.8% during 2025-2031. Rising demand for biologics and increasing demand for cost efficiency and flexibility are noteworthy factors contributing to the expansion of the biopharmaceutical contract manufacturing market size. However, the tightened budget and economic uncertainty hinder the biopharmaceutical contract manufacturing market growth.
Monoclonal antibodies, gene therapies, and cell-based treatments have created the need for more innovative, streamlined manufacturing processes. As a result, contract manufacturing organizations (CMOs) are increasingly adopting advanced technologies such as continuous manufacturing, automation, artificial intelligence (AI), and process analytical technologies (PAT) to enhance production capabilities and meet the growing demand for biopharmaceuticals. Continuous manufacturing is rapidly gaining traction in the biopharmaceutical industry as it allows the uninterrupted production of biologics, providing greater consistency, speed, and efficiency. This process reduces downtime between production runs and minimizes the need for intermediate storage, significantly reducing production costs. According to a Baker McKenzie report, continuous manufacturing can reduce the cost of biologic production by 30%. Novartis and Pfizer are among the major companies implementing continuous manufacturing for large-scale biologic production, demonstrating its effectiveness in improving operational efficiency and reducing costs.
Artificial intelligence (AI) can also be used for process optimization, predictive maintenance, and quality control. AI-based tools can analyze vast amounts of production data in real-time, identifying potential issues before they arise and ensuring optimal conditions throughout the production process. This technology helps CMOs minimize downtime and improve yield rates. Companies such as Cognizant are already using AI to predict potential failures in manufacturing processes and improve decision-making. Furthermore, process analytical technologies (PAT) enable real-time monitoring and control of critical process parameters, ensuring consistent quality across large batches of biologics. By integrating PAT, manufacturers can detect variations early in the production process and adjust in real-time to prevent defects or inconsistencies. This results in higher-quality products and more efficient use of resources, reducing both time and cost. Therefore, the increasing adoption of advanced manufacturing technologies such as continuous manufacturing, automation, AI, and PAT is expected to contribute to the growth of the biopharmaceutical contract manufacturing market in the coming years.
Therapeutic Area-Based Insights
Based on the therapeutic area, the biopharmaceutical contract manufacturing market is segmented into oncology, autoimmune disorders, respiratory disorders, metabolic disorders, neurology, infectious diseases, and others. The oncology segment held the largest biopharmaceutical contract manufacturing market share in 2024. As cancer remains a leading cause of death globally, it drives the need for advanced cancer treatments. According to the World Health Organization (WHO), 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally in 2022. This demand is primarily driven by the development of biologics and the production of biologics involves complex cell culture systems and stringent quality control measures, making outsourcing to contract manufacturers a viable solution for many pharmaceutical companies. Keytruda generated US$ 29.48 billion in sales in 2024, highlighting the immense market potential of oncology biologics. Additionally, the increasing trend toward personalized oncology treatments, particularly with CAR-T therapies such as Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel), has also fueled the need for highly specialized contract manufacturing. These treatments require the production of genetically modified immune cells, which creates the demand for CMOs with expertise in cell and gene therapies, thereby fueling the biopharmaceutical contract manufacturing market growth.
World Health Organization (WHO), Global Autoimmune Institute 2022 report, and International Diabetes Federation are among the primary and secondary sources referred to while preparing the biopharmaceutical contract manufacturing market report.
Table Of Contents
1. Introduction
- 1.1 Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
- 2.1 Analyst Market Outlook
3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
- 3.3 Assumptions and Limitations
4. Biopharmaceutical Contract Manufacturing Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
5. Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics
- 5.1 Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics
- 5.2 Market Drivers:
- 5.2.1 Rising Demand for Biologics
- 5.2.2 Increasing Demand for Cost Efficiency and Flexibility
- 5.3 Market Restraints
- 5.3.1 Tightened Budget and Economic Uncertainty
- 5.4 Market Opportunities
- 5.4.1 Increasing Demand for Personalized Medicine
- 5.5 Future Trends
- 5.5.1 Advanced Manufacturing Technologies
- 5.6 Impact of Drivers and Restraints:
6. Biopharmaceutical Contract Manufacturing Market - Global Market Analysis
- 6.1 Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2021-2031
- 6.2 Biopharmaceutical Contract Manufacturing Market Forecast Analysis
7. Biopharmaceutical Contract Manufacturing Market Analysis - by Product Type
- 7.1 Biologics
- 7.1.1 Overview
- 7.1.2 Biologics: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 7.2 Biosimilar
- 7.2.1 Overview
- 7.2.2 Biosimilar: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
8. Biopharmaceutical Contract Manufacturing Market Analysis - by Source
- 8.1 Microbial
- 8.1.1 Overview
- 8.1.2 Microbial: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 8.2 Mammalian
- 8.2.1 Overview
- 8.2.2 Mammalian: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
9. Biopharmaceutical Contract Manufacturing Market Analysis - by Application
- 9.1 Commercial
- 9.1.1 Overview
- 9.1.2 Commercial: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 9.2 Clinical
- 9.2.1 Overview
- 9.2.2 Clinical: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
10. Biopharmaceutical Contract Manufacturing Market Analysis - by Therapeutic Area
- 10.1 Oncology
- 10.1.1 Overview
- 10.1.2 Oncology: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 10.2 Autoimmune Disorders
- 10.2.1 Overview
- 10.2.2 Autoimmune Disorders: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 10.3 Respiratory Disorders
- 10.3.1 Overview
- 10.3.2 Respiratory Disorders: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 10.4 Metabolic Disorders
- 10.4.1 Overview
- 10.4.2 Metabolic Disorders: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 10.5 Neurology
- 10.5.1 Overview
- 10.5.2 Neurology: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 10.6 Infectious Diseases
- 10.6.1 Overview
- 10.6.2 Infectious Diseases: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 10.7 Others
- 10.7.1 Overview
- 10.7.2 Others: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
11. Biopharmaceutical Contract Manufacturing Market - Geographical Analysis
- 11.1 North America
- 11.1.1 North America Biopharmaceutical Contract Manufacturing Market Overview
- 11.1.2 North America: Biopharmaceutical Contract Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 11.1.2.1 North America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 11.1.2.2 North America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Source
- 11.1.2.3 North America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Application
- 11.1.2.4 North America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Therapeutic Area
- 11.1.3 North America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Country
- 11.1.3.1 United States: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.1.3.1.1 United States: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.1.3.1.2 United States: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.1.3.1.3 United States: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.1.3.1.4 United States: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.1.3.2 Canada: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.1.3.2.1 Canada: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.1.3.2.2 Canada: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.1.3.2.3 Canada: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.1.3.2.4 Canada: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.1.3.3 Mexico: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.1.3.3.1 Mexico: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.1.3.3.2 Mexico: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.1.3.3.3 Mexico: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.1.3.3.4 Mexico: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.2 Europe
- 11.2.1 Europe Biopharmaceutical Contract Manufacturing Market Overview
- 11.2.2 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 11.2.2.1 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 11.2.2.2 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Source
- 11.2.2.3 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Application
- 11.2.2.4 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Therapeutic Area
- 11.2.3 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Country
- 11.2.3.1 Germany: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.2.3.1.1 Germany: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.2.3.1.2 Germany: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.2.3.1.3 Germany: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.2.3.1.4 Germany: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.2.3.2 United Kingdom: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.2.3.2.1 United Kingdom: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.2.3.2.2 United Kingdom: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.2.3.2.3 United Kingdom: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.2.3.2.4 United Kingdom: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.2.3.3 France: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.2.3.3.1 France: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.2.3.3.2 France: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.2.3.3.3 France: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.2.3.3.4 France: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.2.3.4 Italy: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.2.3.4.1 Italy: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.2.3.4.2 Italy: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.2.3.4.3 Italy: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.2.3.4.4 Italy: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.2.3.5 Spain: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.2.3.5.1 Spain: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.2.3.5.2 Spain: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.2.3.5.3 Spain: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.2.3.5.4 Spain: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.2.3.6 Rest of Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.2.3.6.1 Rest of Europe: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.2.3.6.2 Rest of Europe: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.2.3.6.3 Rest of Europe: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.2.3.6.4 Rest of Europe: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.3 Asia Pacific
- 11.3.1 Asia Pacific Biopharmaceutical Contract Manufacturing Market Overview
- 11.3.2 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 11.3.2.1 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 11.3.2.2 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Source
- 11.3.2.3 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Application
- 11.3.2.4 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Therapeutic Area
- 11.3.3 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Country
- 11.3.3.1 China: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.3.3.1.1 China: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.3.3.1.2 China: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.3.3.1.3 China: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.3.3.1.4 China: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.3.3.2 Japan: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.3.3.2.1 Japan: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.3.3.2.2 Japan: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.3.3.2.3 Japan: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.3.3.2.4 Japan: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.3.3.3 India: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.3.3.3.1 India: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.3.3.3.2 India: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.3.3.3.3 India: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.3.3.3.4 India: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.3.3.4 Australia: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.3.3.4.1 Australia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.3.3.4.2 Australia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.3.3.4.3 Australia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.3.3.4.4 Australia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.3.3.5 South Korea: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.3.3.5.1 South Korea: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.3.3.5.2 South Korea: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.3.3.5.3 South Korea: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.3.3.5.4 South Korea: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.3.3.6 Rest of APAC: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.3.3.6.1 Rest of APAC: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.3.3.6.2 Rest of APAC: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.3.3.6.3 Rest of APAC: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.3.3.6.4 Rest of APAC: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.4 Middle East & Africa
- 11.4.1 Middle East & Africa Biopharmaceutical Contract Manufacturing Market Overview
- 11.4.2 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 11.4.2.1 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 11.4.2.2 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Source
- 11.4.2.3 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Application
- 11.4.2.4 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Therapeutic Area
- 11.4.3 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Country
- 11.4.3.1 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.4.3.1.1 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.4.3.1.2 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.4.3.1.3 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.4.3.1.4 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.4.3.2 South Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.4.3.2.1 South Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.4.3.2.2 South Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.4.3.2.3 South Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.4.3.2.4 South Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.4.3.3 United Arab Emirates: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.4.3.3.1 United Arab Emirates: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.4.3.3.2 United Arab Emirates: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.4.3.3.3 United Arab Emirates: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.4.3.3.4 United Arab Emirates: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.4.3.4 Rest of Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.4.3.4.1 Rest of Middle East & Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.4.3.4.2 Rest of Middle East & Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.4.3.4.3 Rest of Middle East & Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.4.3.4.4 Rest of Middle East & Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.5 South & Central America
- 11.5.1 South & Central America Biopharmaceutical Contract Manufacturing Market Overview
- 11.5.2 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 11.5.2.1 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 11.5.2.2 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Source
- 11.5.2.3 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Application
- 11.5.2.4 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Therapeutic Area
- 11.5.3 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Country
- 11.5.3.1 Brazil: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.5.3.1.1 Brazil: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.5.3.1.2 Brazil: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.5.3.1.3 Brazil: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.5.3.1.4 Brazil: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.5.3.2 Argentina: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.5.3.2.1 Argentina: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.5.3.2.2 Argentina: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.5.3.2.3 Argentina: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.5.3.2.4 Argentina: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.5.3.3 Rest of South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.5.3.3.1 Rest of South & Central America: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.5.3.3.2 Rest of South & Central America: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.5.3.3.3 Rest of South & Central America: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.5.3.3.4 Rest of South & Central America: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
12. Competitive Landscape
- 12.1 Heat Map Analysis by Key Players
- 12.2 Company Positioning & Concentration
13. Industry Landscape
- 13.1 Overview
- 13.2 Expansion
- 13.3 New Product Development
- 13.4 Merger and Acquisition
- 13.5 Partnerships
- 13.6 Other Business Strategies
14. Company Profiles
- 14.1 Boehringer Ingelheim International GmbH
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
- 14.2 Lonza Group AG
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
- 14.3 Samsung Biologics Co Ltd
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
- 14.4 Merck KGaA
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
- 14.5 AbbVie Inc
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
- 14.6 WuXi Biologics Inc
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
- 14.7 Ajinomoto Co Inc
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
- 14.8 Cytiva
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
- 14.9 AGC Biologics AS
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
15. Appendix
- 15.1 About The Insight Partners
- 15.2 Glossary of Terms